Compare Cassava Sciences Inc (FLNA) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Cloudflare Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Cloudflare Inc trades at $271.62 (market cap $96.91B). The key difference: Cloudflare Inc is far larger — about 1823.7× Cassava Sciences Inc's market cap, and Cloudflare Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NET | |
|---|---|---|
Market Cap | $53.14M | $96.91B |
Sector | Health | Technology |
52-Week High | $4.64 | $281.69 |
52-Week Low | $1.09 | $160.16 |
Enterprise Value | -$33.43M | $96.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Cloudflare (NET) trades at $274.12, down 2.69% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is robust, reaching $2.17B in 2025, though net margins remain negative at -4.72%. Recent news highlights AI integration in cybersecurity, with a research pilot with OpenAI announced on July 8, 2026, and a Q2 2026 earnings report scheduled for August 6, 2026.
The stock offers growth potential from AI-driven demand but carries valuation risks with a high P/S of 41.06 and negative profitability. Analyst consensus is strongly bullish with a $261 price target, yet competition and cash burn from investing activities pose challenges for sustained equity gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
